These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16139989)

  • 1. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment.
    Tandon R; Fleischhacker WW
    Schizophr Res; 2005 Nov; 79(2-3):145-55. PubMed ID: 16139989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy of second-generation antipsychotics.
    Davis JM; Chen N; Glick ID
    Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
    Foussias G; Remington G
    Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.
    Tandon R; Jibson MD
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():9-26. PubMed ID: 12504069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis.
    Bartoli F; Crocamo C; Di Brita C; Esposito G; Tabacchi TI; Verrengia E; Clerici M; Carrà G
    J Psychiatr Res; 2019 Jan; 108():24-33. PubMed ID: 30447508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic treatment of schizophrenia: an update.
    Bruijnzeel D; Suryadevara U; Tandon R
    Asian J Psychiatr; 2014 Oct; 11():3-7. PubMed ID: 25216917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics for children and young adults: a comparative effectiveness review.
    Seida JC; Schouten JR; Boylan K; Newton AS; Mousavi SS; Beaith A; Vandermeer B; Dryden DM; Carrey N
    Pediatrics; 2012 Mar; 129(3):e771-84. PubMed ID: 22351885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.
    Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU
    Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes.
    Weinmann S; Janssen B; Gaebel W
    J Clin Psychiatry; 2004 Aug; 65(8):1099-105. PubMed ID: 15323596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mount Sinai conference on the pharmacotherapy of schizophrenia.
    Marder SR; Essock SM; Miller AL; Buchanan RW; Davis JM; Kane JM; Lieberman J; Schooler NR
    Schizophr Bull; 2002; 28(1):5-16. PubMed ID: 12047022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.